Cingulate Inc. (CINGW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Chairman of the Board | 570.78k | -- | 1975 |
| Ms. Jennifer L. Callahan CPA | Senior VP, CFO & Secretary | 358.98k | -- | 1971 |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 367.47k | -- | 1957 |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer | -- | -- | 1958 |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer | 244.79k | -- | 1964 |
| Thomas Dalton | Vice President of Investor & Public Relations | -- | -- | -- |
Cingulate Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD; CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children; and CTx-2103 (buspirone) for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available